Advertisement
Advertisement
SGMT
Sagimet Biosciences Inc. Series A Common Stock
9.06
USDSponsored
+0.32
+3.66%
Aug 07, 15:59 UTC -4
Closed
After-Market
9.02
-0.04
-0.50%
SGMT Earnings Reports
Positive Surprise Ratio
SGMT beat 8 of 12 last estimates.
67%
Next Report
Date of Next Report
Aug 19, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.25
Implied change from Q1 26 (Revenue/ EPS)
--
/-24.24%
Implied change from Q2 25 (Revenue/ EPS)
--
/-21.88%
Sagimet Biosciences Inc. Series A Common Stock earnings per share and revenue
On May 12, 2026, SGMT reported earnings of -0.33 USD per share (EPS) for Q1 26, beating the estimate of -0.38 USD, resulting in a 13.57% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.52% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -0.25 USD, with revenue projected to reach -- USD, implying an decrease of -24.24% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Sagimet Biosciences Inc. Series A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.33, beating estimates by 13.57%, and revenue of $0.00, 0% as expectations.
How did the market react to Sagimet Biosciences Inc. Series A Common Stock's Q1 2026 earnings?
The stock price moved down -0.52%, changed from $7.69 before the earnings release to $7.65 the day after.
When is Sagimet Biosciences Inc. Series A Common Stock expected to report next?
The next earning report is scheduled for Aug 19, 2026.
What are the forecasts for Sagimet Biosciences Inc. Series A Common Stock's next earnings report?
Based on --
analysts, Sagimet Biosciences Inc. Series A Common Stock is expected to report EPS of -$0.25 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement